<DOC>
	<DOCNO>NCT02651623</DOCNO>
	<brief_summary>The purpose study demonstrate lack effect sertraline QTc interval relative time-matched placebo healthy subject</brief_summary>
	<brief_title>Study Evaluate The Effect Of Sertraline Cardiac Repolarization Healthy Subjects</brief_title>
	<detailed_description>Evaluate multiple dose 400 mg per day sertraline QTc , evaluate safety tolerability sertraline healthy subject .</detailed_description>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Risk factor QT prolongation torsades de pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>